Second primary malignancies after CAR T-cell therapy: causal attribution, clonal evolution, and risk-adapted surveillance
Year: 2026
Type: article
Abstract: Background Chimeric antigen receptor (CAR) T-cell therapy can produce durable remission in refractory hematologic malignancies, but the expanding survivor population has focused attention on second primary malignancies (SPMs). Interpretation is difficult because recipients already carry substantial age-, disease-, and treatment-related cancer risk; follow-up is often short; outcome definitions vary; and competing mortality is high. Main body This critical review integrates epidemiologic, genomic, mechanistic, and regulatory evidence into a causal framework. Available evidence is consistent with a multistep clonal-evolution model: pre-existing clonal hematopoiesis and cumulative genotoxic injury establish the substrate; lymphodepletion, marrow inflammation, regenerative stress, and altered immune surveillance modify clonal fitness; and additional events permit transformation. Therapy-related myeloid neoplasms are the most actionable subgroup. By contrast, T-cell malignancies derived from CAR-modified cells are exceptionally rare and require direct lineage and vector analysis because detection of a CAR sequence alone does not prove insertional oncogenesis. We propose a graded attribution ladder and a risk-adapted surveillance pathway centered on serial blood counts, prompt evaluation of unexplained cytopenias or lymphoid abnormalities, age-appropriate cancer screening, and mechanism-specific molecular testing. Conclusion Temporal association should not be equated with causation. Prospective denominator-based cohorts, matched comparators, paired biospecimens, integration-site mapping, and single-cell lineage reconstruction are needed to distinguish background risk, treatment-associated clonal selection, and true product-related oncogenesis.
Source: Frontiers in Immunology
Institution: Dongyang People's Hospital
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
Award: G6266304620
OpenAlex ID: W7233733055
